Treatment of Malignant Tumors With NK Cell (NK cell)

Inclusion Criteria:

1. Male or female patients aged 18-70 (including 18 and 70 years old);
2. Those who have been diagnosed as malignant tumor by pathological and histological examination, have received anti-tumor treatment and are in remission;
3. The ECOG score of the patient is less than 2 points;
4. The patient did not receive any chemotherapy, radiotherapy, immunotherapy (such as immunosuppressive drugs) and other anti-tumor treatments within 4 weeks before enrollment, and his previous treatment-related toxicity had returned to grade <1 (hair loss, peripheral nerves) at the time of enrollment Except for low-level toxicity such as inflammation);
5. The patient's intravenous access is unobstructed, which can meet the needs of intravenous drip;
6. The patient voluntarily participates and signs an informed consent form, and follows the research treatment plan and visit plan.

Exclusion Criteria:

1. The patients used high-dose hormones within 1 week before enrollment (except for patients using inhaled hormones);
2. People with severe autoimmune diseases, immunodeficiency diseases or severe allergies;
3. Patients who have been treated with other cellular immune products (DC, T, CTL, CAR-T, etc.);
4. The patient had an uncontrollable infection within 4 weeks before enrollment;
5. Active B HBV DNA>1000copy/mL/C virus hepatitis (anti-HCV positive, HCV RNA positive), HIV positive, syphilis positive;
6. The patient has participated in other clinical studies within 6 weeks before enrollment;
7. Patients suffering from mental illness;
8. The patient has drug abuse/addiction and medical, psychological or social conditions that may interfere with research or have an impact on the evaluation of research results;
9. The patient has alcohol dependence;
10. Women who are pregnant (positive urine/blood pregnancy studies) or breastfeeding; men or women who have a pregnancy plan within the past year; patients cannot be guaranteed to take effective contraceptive measures during the study period;
11. According to the judgment of the investigator, the patient has other conditions that are not suitable for enrollment.